Related Experiment Video

Updated: Jul 5, 2026

Characterization of Vascular Morphology of Neovascular Age-Related Macular Degeneration by Indocyanine Green Angiography
05:14

Characterization of Vascular Morphology of Neovascular Age-Related Macular Degeneration by Indocyanine Green Angiography

Published on: August 11, 2023

[Ranibizumab for treatment of exudative age-related macular degeneration--own experience]

Halina Wykrota1, Ariadna Gierek-Lapińska, Krzysztof Trzciakowski

  • 1Samodzielny Publiczny Szpital Kliniczny Nr 5 Slaskiego Uniwersytetu Medycznego w Katowicach.

Klinika Oczna
|May 21, 2008
PubMed
Abstract

Insights

Ranibizumab injections effectively treat wet age-related macular degeneration (AMD) by inhibiting vascular endothelial growth factor (VEGF). This therapy significantly improves visual acuity in patients with choroidal neovascularization (CNV).

Area of Science:

  • Ophthalmology
  • Vascular Biology
  • Pharmacology

Context:

  • Neovascular age-related macular degeneration (AMD) pathogenesis involves angiogenesis factors.
  • Traditional treatments for subfoveal choroidal neovascularizations (CNV) included photodynamic therapy (PDT).
  • Vascular Endothelial Growth Factor (VEGF) inhibitors represent a novel therapeutic approach for neovascular AMD.

Purpose:

  • To evaluate the efficacy and safety of intravitreal ranibizumab for treating CNV secondary to AMD.
  • To assess changes in visual acuity and vision loss in patients receiving ranibizumab treatment.

Summary:

  • Intravitreal ranibizumab (0.5 mg) was administered monthly for three doses, followed by as-needed retreatment based on monthly follow-ups.
  • The study included 67 eyes of 67 patients with various angiographic subtypes of wet AMD.
  • Mean visual acuity improved by +12.4 ETDRS letters, with 93.2% of patients losing fewer than 15 letters and 43.4% gaining more than 3 letters.

Impact:

  • Intravitreal ranibizumab demonstrates significant effectiveness in treating CNV associated with AMD.
  • The therapy leads to substantial visual acuity improvement in a considerable number of patients.
  • Anti-VEGF therapy offers new hope for previously untreatable ocular diseases.

Related Concept Videos

Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...